EP3848460 - ANTISENSE OLIGONUCLEOTIDE TARGETING ARL4C MOLECULE, AND NUCLEIC ACID DRUG USING ANTISENSE OLIGONUCLEOTIDE [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 11.06.2021 Database last updated on 08.10.2024 | |
Former | The international publication has been made Status updated on 14.03.2020 | Most recent event Tooltip | 24.09.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Osaka University 1-1, Yamadaoka Suita-shi, Osaka 565-0871 / JP | For all designated states National Institutes of Biomedical Innovation, Health and Nutrition 7-6-8, Saito-Asagi Ibaraki-shi, Osaka 567-0085 / JP | For all designated states National University Corporation Kobe University 1-1 Rokkodai-cho Nada-ku Kobe-shi, Hyogo 657-8501 / JP | [2021/28] | Inventor(s) | 01 /
KIKUCHI, Akira c/o OSAKA UNIVERSITY 1-1, Yamadaoka Suita-shi, Osaka 565-0871 / JP | 02 /
MATSUMOTO, Shinji c/o OSAKA UNIVERSITY 1-1, Yamadaoka Suita-shi, Osaka 565-0871 / JP | 03 /
OBIKA, Satoshi c/o NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION HEALTH AND NUTRITION 7-6-8, Saito-Asagi Ibaraki-shi, Osaka 567-0085 / JP | 04 /
KASAHARA, Yuya c/o NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION HEALTH AND NUTRITION 7-6-8, Saito-Asagi Ibaraki-shi, Osaka 567-0085 / JP | 05 /
FUKUMOTO, Takumi c/o NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY 1-1, Rokkodai-cho, Nada-ku Kobe-shi, Hyogo 657-8501 / JP | [2021/28] | Representative(s) | Müller-Boré & Partner Patentanwälte PartG mbB Friedenheimer Brücke 21 80639 München / DE | [2021/28] | Application number, filing date | 19856678.8 | 04.09.2019 | [2021/28] | WO2019JP34746 | Priority number, date | JP20180165544 | 05.09.2018 Original published format: JP 2018165544 | [2021/28] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020050307 | Date: | 12.03.2020 | Language: | JA | [2020/11] | Type: | A1 Application with search report | No.: | EP3848460 | Date: | 14.07.2021 | Language: | EN | [2021/28] | Search report(s) | International search report - published on: | JP | 12.03.2020 | (Supplementary) European search report - dispatched on: | EP | 04.01.2023 | Classification | IPC: | C12N15/113, A61K31/7115, A61K31/712, A61K31/7125, A61K48/00, A61P35/00, A61P35/04 | [2021/28] | CPC: |
A61K31/713 (EP);
C12N15/1137 (EP,US);
A61P35/00 (EP);
A61P35/04 (EP,US);
C12N15/113 (EP);
C12Y207/01137 (EP);
C12N2310/11 (EP,US);
C12N2310/14 (EP);
C12N2310/315 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/28] | Title | German: | GEGEN ARL4C-MOLEKÜL GERICHTETES ANTISENSE-OLIGONUKLEOTID UND NUKLEINSÄUREARZNEIMITTEL MIT ANTISENSE-OLIGONUKLEOTID | [2021/28] | English: | ANTISENSE OLIGONUCLEOTIDE TARGETING ARL4C MOLECULE, AND NUCLEIC ACID DRUG USING ANTISENSE OLIGONUCLEOTIDE | [2021/28] | French: | OLIGONUCLÉOTIDE ANTISENS CIBLANT UNE MOLÉCULE D'ARL4C, ET MÉDICAMENT À BASE D'ACIDE NUCLÉIQUE UTILISANT UN OLIGONUCLÉOTIDE ANTISENS | [2021/28] | Entry into regional phase | 04.03.2021 | Translation filed | 11.03.2021 | National basic fee paid | 11.03.2021 | Search fee paid | 11.03.2021 | Designation fee(s) paid | 11.03.2021 | Examination fee paid | Examination procedure | 11.03.2021 | Examination requested [2021/28] | 21.07.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 31.03.2021 | Renewal fee patent year 03 | 19.09.2022 | Renewal fee patent year 04 | 20.09.2023 | Renewal fee patent year 05 | 24.09.2024 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2016027029 (ACOBIOM [FR]); | International search | [YA]JP2015231978 (UNIV OSAKA); | by applicant | WO2014046212 | WO2015125783 | WO2016017422 |